With the third quarter now in the rear-view mirror and the November elections firmly in view as a potential upside/downside catalyst, many investors are wondering where the market might head next.
In addition to asking that question, investors are also eagerly watching the news flow emanating from Diamondback Energy Inc (NASDAQ:FANG), Depomed Inc (NASDAQ:DEPO), Las Vegas Sands Corp. (NYSE:LVS), MGM Resorts International (NYSE:MGM), and Wynn Resorts, Limited (NASDAQ:WYNN). In this article, we’ll take a closer look at the five companies and their associated catalysts and use the latest 13F data to see how the smart money was positioned in the equities at the end of the second quarter.
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).
Diamondback Energy Inc (NASDAQ:FANG) is in the spotlight after the Wall Street Journal reported that the firm is near a deal to purchase Silver Hill Energy Partners for potentially $2.5 billion. A deal could be announced as early as next week if another bidder doesn’t emerge with a better offer and the current deal doesn’t fall apart. Silver Hill owns the rights to drilling in acreage in the lucrative Permian Basin, which sports some of the lowest shale production costs in the country. Steve Cohen‘s Point72 Asset Management upped its stake in Diamondback Energy Inc (NASDAQ:FANG) by 6,455% during the second quarter to 131,100 shares at the end of June.
Traders are watching Depomed Inc (NASDAQ:DEPO) after judge Claire Cecchi of the United States District Court for the District of New Jersey ruled in favor of Depomed in the company’s patent litigation against all three filers of Abbreviated New Drug Applications for Depomed’s Nucynta franchise, Actavis, Alkem Laboratories Limited and Roxane Laboratories. With the court’s ruling, Depomed expects market exclusivity until December 2025 for Nucynta ER, Nucynta and Nucynta oral solution. The ruling is important because the Nucynta franchise accounts for roughly two-thirds of the company’s product sales. With the uncertainty removed, some investors think Depomed can proceed with its strategic alternatives, including a potential sale or merger. 23 hedge funds in our database were long $328.2 million worth of Depomed Inc (NASDAQ:DEPO) shares at the end of June, which accounted for 27.40% of the float.
On the next page, we’ll examine why investors are closely watching Las Vegas Sands, MGM Resorts, and Wynn Resorts.